HSP90 inhibitors promote cell death by degrading Met and BCR::ABL1 in both imatinib-resistant and -sensitive chronic myeloid leukemia cells. - Tsubaki, Masanobu; Matsuo, Taira; Komori, Rie; Nagai, Noriaki; Yamamoto, Tetsushi; Nishida, Shozo (Future Journal of Pharmaceutical Sciences, 2025)